Helicobacter pylori infection
Conditions
Interventions
Experimental Group:Vonoprazan 20mg twice daily and Amoxicillin 1000mg three times daily for 10 days
Control Group:Rabeprazole 10mg twice daily+ Bismuth potassium citrate 240mg twice daily + Amoxicillin 1000mg twice daily + Clarithromycin 500mg twice daily for 14 days
Sponsors
Wuxi Ninth People's Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: This study targets individuals from community populations served by participating healthcare institutions. Eligible participants must meet all of the following criteria: 1. Aged 18 to 70 years; 2. Positive result for the ¹³C or ¹4C urea breath test within the past month. 3. Diagnosed with Helicobacter pylori-positive chronic gastritis by endoscopy within the past three months and meets the indications for H. pylori eradication as outlined in the Sixth National Consensus Report on the Management of Helicobacter pylori Infection; willing to undergo eradication therapy. 4. No prior history of H. pylori eradication therapy. 5. Signed informed consent form.
Exclusion criteria
Exclusion criteria: This study targets individuals from community populations served by participating healthcare institutions. Participants will be excluded if they meet any of the following criteria: 1. Allergy to medications used in this clinical trial; 2. Use of P-CAB,PPI, histamine H2-receptor antagonists, antibiotics, bismuth, or probiotics 1 months before initiating study treatment; 3.Female patients planning pregnancy, as well as pregnant and breastfeeding patients; 4. Use of adrenocorticosteroids, nonsteroidal anti-inflammatory drugs, and anticoagulants; 5. Presence of diseases or clinical conditions, such as cardiac vascular disease,lung disease, liver disease,kidney disease, metabolic disease, mental illness, or malignant tumors, that might interfere with the evaluation of study treatment; 6. Previous esophageal or stomach surgical procedures; 7. Incomplete follow-up or noncompliance with the study treatment;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| eradication rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Patient compliance;Incidence of adverse reactions;cost-effectiveness; | — |
Countries
China
Contacts
Public ContactLeyao Zhang
Department of Gastroenterology, Wuxi Ninth People's Hospital Affiliated to Soochow University
Outcome results
None listed